Metformin Market Size Forecast: Revenue and CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Metformin Industry Expected To Reach By 2029, Starting From 2025 Levels?

The metformin market has demonstrated significant growth over recent years. It is projected to expand from $4.17 billion in 2024 to $4.44 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been driven by a rise in the prevalence of diabetes, an increase in awareness of the disease, and growing healthcare spending.

The metformin market is projected to experience substantial expansion in the coming years. By 2029, it is anticipated to reach a valuation of $5.68 billion, demonstrating a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period stems from factors such as the burgeoning expansion into emerging markets, rising awareness and uptake of metformin, an aging global populace, the impact of patent expiry and subsequent generic competition, a surge in demand for combination therapies, and heightened awareness regarding side effects and safety considerations. Key trends influencing this period encompass the introduction of novel products, the prevalence of lifestyle interventions, continuous efforts in research and development, a rise in strategic partnerships, and ongoing advancements in manufacturing technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16475&type=smp

Which Industry Drivers Are Expected To Accelerate The Metformin Market From 2025 To 2029?

The rising incidence of diabetes is projected to stimulate the future expansion of the metformin market. Diabetes is a medical condition characterized by either the pancreas producing inadequate insulin or the body’s inability to effectively use the insulin it makes. Several elements contribute to the widespread occurrence of diabetes, such as the global obesity crisis, genetic predispositions, shifts in lifestyle, insufficient access to healthcare, and exposure to specific toxins. Metformin aids in controlling type 2 diabetes by decreasing blood sugar, supporting weight reduction, enhancing insulin sensitivity, and possibly delivering further cardiovascular benefits. As an illustration, in February 2023, Diabetes Canada, a non-profit organization headquartered in Canada, indicated that the estimated prevalence of diabetes in Canada is anticipated to rise from 2,409,000 cases (15% of the population) in 2023 to 3,009,000 cases (17% of the population) by 2033. Thus, the escalating prevalence of diabetes is a significant driver for the growth of the metformin market.

What Are The Primary Types Of Segments Analyzed In The Metformin Market?

The metforminmarket covered in this report is segmented –

1) By Product Type: Standard-Release Tablets; Slow-Release Tablets

2) By Dosage Type: 500MG; 750MG; 850MG; 1G

3) By End-user: Clinics; Hospitals; Homecare; Other End-Users

Subsegments:

1) By Standard-Release Tablets: 500 Mg; 850 Mg; 1000 Mg

2) By Slow-Release Tablets: 500 Mg; 750 Mg; 1000 Mg

Which Key Trends Are Expected To Influence The Metformin Market In The Coming Years?

Leading companies operating in the metformin market are prioritizing the development of innovative diabetes medications, such as triple-drug FDC, to enhance their market position. A triple-drug Fixed-Dose Combination (FDC) for diabetes medications typically refers to a single tablet or capsule that integrates three distinct antidiabetic medications. These combinations are designed to offer synergistic effects in managing blood sugar levels and improving overall glycemic control in patients with Type 2 diabetes. For example, in October 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced India’s first triple-drug fixed-dose combination (FDC) featuring teneligliptin with dapagliflozin and metformin. This FDC, branded as Zita DM, contains teneligliptin (20 mg), dapagliflozin (10 mg), and metformin SR (500 mg/1000 mg) in a fixed dose. Its purpose is to improve glycemic control in adult patients with Type 2 diabetes, especially those whose diabetes remains uncontrolled by metformin or who require the addition of teneligliptin and dapagliflozin as separate drugs.

Who Are The Core Companies Influencing The Metformin Market Landscape?

Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Jai Radhe Sales, Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., Shree Sadguru, LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Aastrid International Pvt. Ltd., Abhilasha Pharma, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Gangwal Healthcare, Granules India Limited, Alekhya Drugs Pvt. Ltd, Angels Pharma India Private Limited, Auro Laboratories Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/metformin-global-market-report

How Does The Metformin Market Perform Across Key Geographic Regions?

North America was the largest region in the metformin market in 2024. The regions covered in the metformin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Metformin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16475&type=smp

Browse Through More Reports Similar to the Global Metformin Market 2025, By The Business Research Company

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Flow Cytometry Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/flow-cytometry-global-market-report

Vital Parameter Monitoring Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vital-parameter-monitoring-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795